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Summary The effect of photodynamic therapy (PDT) on tumour perfusion in both anaplastic (R3327-AT)
and well differentiated (R3327-H) Dunning prostatic tumours was studied using the radiopharmaceutical
99Technetium hexamethylpropyleneamine oxime (99"Tc-HMPAO). Tumours in the left flanks of rats (Copen-
hage x Fischer, F1 hybrids) were treated with interstitial PDT when their volumes reached 2-3 cm3.
Qualitative and quantitative data from pre- and post-PDT scintigraphy revealed a light-dose-dependent
shut-down of tumour perfusion which was also time-dependent. Maximal shut-down, following a 1,600J
light-dose, occurred about 8 h post-PDT. Light exposure 2 h after the intravenous administration of the
photosensitiser (Photofrin II) produced a greater vascular shut-down than did light exposure 24 h after the
administration of the drug. Regional differences in perfusion within treated and non-treated tumours were
measured by tomographic procedures. Light-dose-dependent volumes of perfusion shut-down were demon-
strated in addition to the naturally occurring regional differences in tumour perfusion. This radiopharma-
ceutical may have future utility for monitoring the clinical treatment of solid tumours with PDT.
Photodynamic therapy (PDT) can kill cells by both direct
and indirect mechanisms. Direct killing, in vitro, can result
from singlet oxygen damage to biomembranes (Bertolini et
al., 1984; Grossweiner, 1984). In particular, damage to lyso-
somes (Torinuki et al., 1980; Volden et al., 1981; Santus et
al., 1983; Reyftmann et al., 1986) results in cell autolysis and
damage to mitochondria (Sandberg et al., 1982; Burns et al.,
1982; Singh et al., 1987) results in disruption of oxidative
phosphorylation. Indirect killing, in vivo, can result from
microvascular damage causing cessation of blood flow and
secondary tumour cell death (Henderson et al., 1985; Selman
et al., 1984).
This research group has previously reported on the poten-
tiation of PDT by misonidazole, a bioreductive cytotoxin, in
the treatment of Dunning prostate tumours (Gonzalez et al.,
1986). Subsequent investigations confirmed this finding for
both well differentiated and anaplastic tumours and showed a
PDT-dependent binding of tritiated misonidazole to both
normal and tumour tissues (Hirsch et al., 1987). These find-
ings are consistent with PDT-induced tissue hypoxia and
subsequent cell killing by adjuvant bioreductive chemo-
therapy.
If PDT is to become a modality of therapy for solid
tumours, non-invasive assays which can measure the extent
of PDT-induced vascular shut-down could play a useful role
in its development. We therefore undertook a study to inves-
tigate PDT-induced vascular shut-down in both well-perfused
and poorly-perfused Dunning prostate tumours using scinti-
graphy with the radiopharmaceutical 99Technetium hexa-
methylpropyleneamine oxime (9Tc-HMPAO). 99Tc-HMPAO
has been shown by Hammersley et al. (1987) to be a good
marker of tumour perfusion in experimental tumours and
was used by Rowell et al. (1989) to assess blood flow in
human lung tumours. This non-invasive technique for moni-
toring PDT-induced vascular shut-down may have use in the
clinic for estimating the extent and kinetics of perfusion
shut-down. These parameters would be important for
monitoring early treatment response and for scheduling
adjuvant bioreductive chemotherapy targeted at naturally-
occurring and induced hypoxia.
Materials and methods
Tumour model
The Dunning prostatic tumour model was initially isolated
by Dr W.H. Dunning when it occurred spontaneously in a
breeder rat (Dunning, 1963). Since initial isolation, several
sublines have been developed and well characterised (Isaacs,
1987). The two sublines used in this study, the R3327-H and
R3327-AT, represent the extremes of differentiation. The
R3327-H tumour obtained from the Papanicolaou Institute
(Miami, FL) is well differentiated, hormonally sensitive, dip-
loid and slow growing with a doubling time of 12-20 days.
The R3327-AT tumour obtained from Dr D. Coffey of John
Hopkins University (Baltimore, MD), is anaplastic, hormon-
ally insensitive, aneuploid, and rapidly growing with a doubl-
ing time of 2-3 days.
The tumours were maintained by serial passage in Fl
males from matings of Fischer 344 (female) x Copenhagen
2331 (male) rats. The animals were bred by the University of
Alberta Health Sciences Laboratory Animal Services from
breeder stock obtained from Harlan Spargue, Dawley Inc
(Indianapolis, IN) and were cared for in accordance with the
guidelines of the Canadian Council on Animal Care. Donor
tissue was selected from tumours that had been monitored
for growth characteristics and histological appearance (grade)
in order to avoid tumour drift. Using aseptic technique,
selected tumour pieces of approximately 1 mm3 were implant-
ed surgically into the left flanks of animals greater than 6
weeks of age, as previously described (Thorndyke et al.,
1985). Following grafting, a latency period of 1-2 weeks for
the anaplastic tumours and 4-5 months for the well differ-
entiated tumour was observed. Tumour dimensions were
measured with calipers in three mutually perpendicular direc-
tions while the animals were lightly anesthetised and tumour
volumes calculated using the formula V = n/6 x D, x D2 x D3
as described elsewhere (Mador et al., 1982). Tumours were
treated at volumes between 2-3 cm3 unless otherwise indic-
ated.
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Anesthetics
All procedures were approved by the local animal care com-
mittee and were performed under general anesthesia. For
short-term anesthesia (i.e., tumour measurement and tumour
implantation) inhalation Halothane was employed. For anes-
thesia of intermediate duration, Ketamine (75 mgkg-') and
Xylazene (7.5 mg kg-') were administered intraperitoneally.
For the prolonged anesthesia required for PDT and scinti-
graphy the animals were induced with Ketamine 12 mg kg-'
and Xylazene 1.0 mg kg-' i.v. via an indwelling tail vein
catheter and maintained with a constant infusion of Keta-
mine (25mgkg-'h-') and Xylazene (2.0mgkg-'h-'). The
animals undergoing prolonged anesthesia were also given
Atropine (0.05 mg kg-' i.m.) to dry up pulmonary secretions.
Photosensitiser
Photofrin II (Pll) was obtained from QuadraLogic Techno-
logies (Vancouver, Canada) in frozen isotonic saline (2.5 mg
ml-'). One bottle of this drug was thawed and dispensed into
2.5 ml aliquots and stored frozen, protected from light, until
the time of use. PII was administered at 15 mg kg-' i.v. 2 h
prilor to PDT in all studies except for the experiment which
compared the magnitude of perfusion shut-down following
light exposure at 2 or 24 h post-photosensitiser administra-
tion. In this experiment the new lyophilised Photofrin
(MRWO #P89-0089) was used, also obtained from Quadra-
Logic Technologies (Vancouver, Canada). This lyophilised
preparation of drug was dissolved in 30 ml of sterile 5%
dextrose and water to a final concentration of 2.5 mg ml-'
and stored in frozen aliquots. It was administered at 7.5 mg
kg-' because of its demonstrated increase potency in vitro
(Chapman et al., 1991).
Interstitialphototherapy
The light source used in these experiments was a Coherent
CR-599 argon driven dye laser tuned to 630 nm with a
maximum output of 4 Watts. The monochromatic light beam
was split into eight beams of equal intensity and directed
down 600 micron quartz optical fibres with 1.5 cm cylindrical
diffusing tips (Arnfield et al., 1986). Interstitial phototherapy
was carried out with seven of these fibres inserted into acetal
plastic needles which were implanted into the tumour
through a template, in an hexagonal pattern of equilateral
triangles, 8 mm apart. A LaserguideTm power meter was used
to assess the power output of each fibre and to confirm the
wavelength which was set using a SPEXTm monochromator.
The 8th fibre was placed in the power meter to continuously
monitor the power output. The power output (dose rate) was
kept constant at approximately 90 mW fibre and the time of
exposure was varied to yield different light-doses as required.
Tumour temperature
To prevent against hyperthermic effects, a 27 gauge copper-
constain thermal couple (OmegaTm) was inserted into the
tumour and temperatures were monitored during photo-
therapy to ensure that core temperature did not exceed 400C.
External cooling with 70% isopropyl alcohol was employed if
the intratumour temperature reached 40°C; however, this was
a rare problem at a dose rate of 90 mW fibre.
Scintigraphy
99"Tc-HMPAO was prepared from a kit (CeretecTm, Amer-
sham International) by adding 5 ml of second elution 99mTc
sodium pertechnetate (90 MBq ml-') to a lyophilised pre-
paration of HMPAO in stannous chloride. Labelling effici-
ency of the lipid soluble complex was assayed by a two phase
immiscible partition of 0.9% saline and ethyl acetate (Ball-
inger et al., 1988). A lipid phase which contained greater
than 90% activity was considered acceptable and the pre-
paration used within +h. One ml (90 MBq) of the radio-
pharmaceutical was administered i.v. via an indwelling tail
vein catheter and the catheter flushed with 1 ml of normal
saline. After allowing a minimum of 5 min for distribution,
static images were obtained by placing the animal both
supine and prone on the the low-energy high-resolution col-
limator of a General Electric (StarportTm) 400 AC gamma-
camera. With a 129-151 KeV window, 10 min images were
acquired on a Picker PCS 512 computer using a 128 by 128
matrix. Quantitative data on regional activity were obtained
from the digitised image using the region of interest (ROI)
program. When comparing ROIs, the pixel area was kept
constant and the posterior and anterior activities were
average to reduce subjective error and error resulting from
overlying activity in other organs.
Tomography
In an attempt to interpret local failures following interstitial
PDT, regional differences in perfusion of treated and non-
treated tumours were measured. Since the resolution of single
photon emission computed tomography (SPECT) was close
to the dimensions of the tumours, the tumours were excised,
solidified in a dry ice and 70% isopropyl alcohol slurry and
serially sectioned into 2 mm slices. The slices were then
placed, in proper orientation, directly on the low-energy
high-resolution collimator of the gamma-camera, magnified
x 2 and images acquired for 30 min on a 128 x 128 com-
puter matrix to produce tomograms of the tumour. The
computer images were enlarged to produce a pixel size
representative of approximately 1 mm.
Isodoseplots
Light dosimetry in tumour used for tomographic studies were
determined and compared with regional perfusion shut-down.
Light intensity measurements were obtained with a miniature
light detector placed at known depths within the acetal plas-
tic needles immediately prior to PDT of the tumour. The
light intensity measurements for each tumour were inter-
polated to produce isodose plots in several planes perpendic-
ular to the cylindrical diffusing fibres as described elsewhere
(Arnfield et al., 1989).
Experimentalprotocol
Animals were randomised to specific treatments when their
tumours reached volumes of between 2-3 cm3. A lateral tail
vein was cannulated percutaneously with a 24 gauge (Bax-
terTm) teflon catheter. The catheter was capped with a PRNTm
heparin lock and the tail was covered with a protective
copper-tinned coaxial sheath. Each animal served as its own
control by being imaged with 99mTc-HMPAO before and
after PDT. There was no manipulation of the tumour (i.e.
needle insertion) prior to PDT. Following pretreatment imag-
ing, the tail vein catheter was injected with 0.3 ml ofHeparin
(100 unitsml-') and the rat placed in a metabolic isolation
cage. Eight half-lifes (T1 = 6.05 h) of isotope decay were
allowed to pass prior to PDT and repeat imaging. Animals
were treated with PDT at varying light-doses and imaged 1 h
post-treatment, except for the time-dependency studies where
the animals were imaged at various times post-PDT after a
constant dose of 1,600J. Animals were then followed post-
PDT for tumour growth, except for those sacrificed for
tomographic studies. Control tumours that received no
therapy were also included for comparison of normal growth
rates.
Results
This study yielded both qualitative and quantitative data
on PDT-induced vascular shut-down. Figure Ia shows a
pre-PDT scintigram of a rat bearing the well differentiated
R3327-H tumour in its left flank. This tumour is quite well
perfused when compared to the essential organs, with aSCINTIGRAPHY OF PDT INDUCED PERFUSION SHUT-DOWN 493
Figure 1 Digitised planar 99mTc-HMPAO scintigrams of a rat bearing the R3327-H tumour (white arrows) in his left flank a,
pre-PDT and b, 8 h post-PDT at 1600 J.
tumour/brain ratio of about 0.7. Figure lb is a post-PDT
scintigram of the same animal 8 h following PDT at 1,600 J.
There is virtually no perfusion to the tumour and perfusion
to the surrounding normal tissue is also diminished. Like-
wise, Figure 2a is a pre-PDT scintigram of a rat bearing the
anaplastic R3327-AT tumour in its left flank. This tumour is
less well perfused relative to the R3327-H tumour. Figure 2b
is a post-PDT scintigram of the same animal 1 h following
PDT at 1,600 J. Again there is a perfusion deficit involving
the treated tumour and surrounding normal tissue.
Quantitative data was obtained using the ROI program.
Figure 3a and 3b demonstrate ROIs in which activities were
measured to estimate perfusion of R3327-AT and R3327-H
tumours, respectively. These tumour/brain ratios show that
the well differentiated tumour, on average, is 1.77 x better
perfused than the anaplastic tumour (Table I). Quantitative
analyses of pre- and post-PDT scintigrams demonstrate a
light-dose and time-dependent vascular shut-down for both
the R3327-H and R3327-AT tumours. Figure 4 shows the
light-dose-dependency of vascular shut-down to be similar
for both tumours. Data points have been normalised to
pretreatment perfusion levels which are significantly different
for the two tumours (Table I). Light-dose-dependent vascular
shut-down and tumour response in the R3327-AT tumour
appear to correlate (Table II).
The temporal relationship of vascular shut-down was stud-
ied using both anaplastic and well differentiated tumours.
The tumours were treated at a constant light-dose of 1,600 J
and imaged at various times post-PDT. The results are
depicted as per cent initial perfusion vs time in Figure 5.
Maximal shut-down occurs about 8 h post-PDT in both
tumours and remains niaximally infarcted at 24 h after this
light-dose.
Tomographic studies were performed with anaplastic
tumours whose volumes were approximately 4cm3 so that
boundaries and regional differences in vascular perfusion
could be observed. A control tumour, receiving interstitial
light only (no PIT), was included in each study. Both animals
were treated with 2,400 J and received an equal dose of the
radiopharmaceutical 99mTc-HMPAO (prepared from the same
kit) 1 h post-PDT. Figure 6a shows intratumour distributions
of radioactivity in a treated tumour (upper two rows) and in
a control tumour (lower two rows). In the treated tumour a
region of perfused tissue surrounds that adjacent to the
illuminators and probably represents the limit of 'effective'
630 nm light exposure. Perfusion was lower in the periphery
of the lased tumour compared to the non-lased tumour and
this effect would become amplified at longer times, similar to
results shown in Figure 5. Therefore a seven fibre icosohedral
array with a 8 mm spacing will be limited to treating tumours
of 2-3 cm3 with attenuation and perfusion properties similar
to the R3327-AT tumour. Indeed, if 991Tc-HMPAO per-
fusion can be considered a marker of biologically effective
light penetration, then the regional limitation of perfusion
shut-down should relate to the isodose plots of this tumour
as shown in Figure 6b. The black line forming the ellipsoid
around the isodose plots represents the tumour boundary as
measured with calipers. The minimum dose required to pro-
duce acute vascular shut-down (1 h post-PDT) appears to
correspond with the 35 J cm-2 isodose line which is about
3 mm from the surface of each illuminator.
Since these studies were designed to measure vascular
damage, we administered the light-dose 2 h following admin-
istration of PIT when the drug concentration is maximal in494 R.B. MOORE et al.
Figure 2 Digitised planar 9mTc-HMPAO scintigrams of rat bearing the R3327-AT tumour (white arrow) in his left flank a,
pre-PDT and b, 1 h post-PDT at 1600 J.
the blood pool as demonstrated by Paramsothy et al. (1989).
Clinical phototherapy however, is normally applied 24-72 h
after photosensitiser administration in an attempt to exploit
maximum tumour/normal tissue ratio of photosensitiser. We
therefore, also measured vascular shut-down when photo-
therapy was applied 24 h following administration of PII.
Perfusion shut-down with phototherapy at 2 h was, on aver-
age, 35% greater than that observed at 24 h following
administration of PII (Table III). This difference in perfusion
shut-down was significantly different for the two groups
(Student's t-test, 0.02).
Discussion
Tumours with two extremes of tumour differentiation were
chosen for these experiments because of their different pro-
liferation kinetics and inherent perfusion which might influ-
ence PDT response. Previous experiments had shown that the
R3327-AT tumour is more resistant to ionising radiation
than its well differentiated counterpart, the R3327-H tumour
(Mador et al., 1982; Thorndyke et al., 1985). The increased
radioresistance of the R3327-AT tumour was attributed to a
15-25% hypoxic fraction, demonstrated by '4C-Misonidazole
labelling. Little or no hypoxia was observed in well differ-
entiated tumours of up to 3 cm3 with this hypoxic marker
(Thorndyke et al., 1985).
In this current study, comparison of tumour/brain ratios of
the perfusion radiopharmaceutical, 99mTc-HMPAO, revealed
that the well differentiated tumour on average is 1.77 x better
perfused than the anaplastic tumour. Since PDT is also
dependent on oxygen for cell killing (Moan et al., 1985;
Mitchell et al., 1985) it might be hypothesised that the ana-
plastic tumour would be more resistant to PDT. In fact,
previous studies by Hirsch et al. (1987) had shown the
R3327-H tumours to respond better to PDT than did the
R3327-AT tumour at equal photofrin and light-doses. Our
measurements of perfusion shut-down have failed to demon-
strate a measurable difference in tumour response to PDT.
Both tumour sublines displayed a similar fractional shut-
down of perfusion as a function of light-dose and time.
The tomographic studies showed that the penetration of
(effective' light required to produce acute vascular shut-down
after a total dose of 2,400 J is limited to tumour zones within
3 mm from each illuminator. When compared with the light
dosimetry, this zone ofperfusion shut-down corresponds to a
threshold dose of about 35 J cm-2. The light-doses delivered
to the effected tumour tissue boundary ranged from 100 to
35Jcm2 as a consequence of the rapid fall off in light
intensity resulting from spacial dilution and tissue attenua-
tion, as well as, the limited resolution of the assay. Other
factors which can contribute to the heterogeneity of this
biological effect are non-uniform PII distribution and vari-
able tissue oxygenation resulting from regional differences in
tumour perfusion. Our light fluence values for PDT effect,
however, coincide well with other reported values. Tromberg
et al. (1990) used transcutaneous oxyen electrodes to monitor
02 consumption and depletion by PDT and reported a mini-
mal fluence of 20-25 J cm-2 to produce permanent vascular
collapse with a PII dose of 10 mgkg-'. Wieman et al. (1988)
studied blood flow by laser dopler techniques and dye exclus-
ion and reported a minimal light-dose of 22.5 Jcm2 toSCINTIGRAPHY OF PDT INDUCED PERFUSION SHUT-DOWN 495
Figure 3 Digitised planar 99mTc-HMPAO scintigrams demonstrating the ROIs within tumour and brain used to measure
tumour/brain ratios in R3327-AT tumour a, and the R3327-H tumour b.
produce permanent vascular collapse with a PII dose of
10 mg kg-'. Hilf et al. (1987) using 31P-NMR and Star et al.
(1986) using sandwich observation chambers have reported
higher values of 54Jcm-2 and 72Jcm2, respectively, to
produce permanent vascular changes. This experimental
agreement on 'effective' light-dose for PDT response is sur-
prisingly good when one considers that diverse biological
systems, with differing vascularisation, were utilised in the
different studies. c
Although near complete vascular shut-down at 1 h post- °
PDT (2,400 J total dose) was limited to a light penetration of
about 3 mm, a significant decrease in perfusion was noted
beyond this distance. This could theoretically be the result of
lower light fluence or the diffusion of vasoactive substances
a)
a.
Table I Tumour to brain ratios of99mTc-HMPAO as a measure of
R3327-AT and R3327-H tumour perfusion
R3327-H R3327-AT
0.623 0.302
0.755 0.353
0.777 0.322
0.661 0.376
0.550 0.252
0.747 0.258
0.692 0.492
0.933 0.538
0.566 0.408
0.604 0.495
0.629 0.476
Mean value 0.69± 0.11 0.39±0.10; P=<0.001
Total light dose (joules)
*R3327-AT * R3327-H
Figure 4 Linear regression plot of per cent initial perfusion+
standard deviation (n = 3) as a function of light-dose in the well
differentiated R3327-H and anaplastic R3327-AT tumours.496 R.B. MOORE et al.
Table II R3327-AT tumour growth delay post PDT: days to reach
10 x treatment volume and cures
Treatment Growth delay Cures
Control 16.4± 1.2 0/14
800 Joule 28.0±7.4 0/8
1600 Joule 36.0±8.9 0/8
2400 Joule 41.0±5.2 1/5
3200 Joule 20 2/3
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Figure 5 Histogram of per cent initial perfusion±standard
deviation (n = 3) as a function of time after PDT at 1600 J for
both the R3327-AT and R3327-H tumour.
released by PDT (Fingar et al., 1990; Henderson et al., 1989).
Whatever the cause of this moderate tumour ischemia, it
could become a target for bioreductive chemotherapy for
potentiation of PDT response (Gonzalez et al., 1986; Henry
et al., 1989).
The overall significance of these nuclear medicine studies is
that 9'Tc-HMPAO might be usefully employed in clinical
situations to monitor the degree and extent of PDT induced
vascular shut-doWn using SPECT. Since tumour response is
difficult to predict because of intra- and inter-tumour hetero-
geneity in the distributions of PII, activating light and
oxygen, a non-invasive measure of tumour response would
assist in prescribing adequate treatment. The time-depen-
dence of vascular shut-down in this study, revealed a maxi-
mal effect about 8 h after PDT. An interval of this duration
would allow for post-PDT adjuvant chemotherapy prior to
maximal shut-down, thus ensuring drug delivery and avoid-
ing interaction with the photo-oxidation process. This inter-
val prior to the perfusion nadir differs from the studies of
Wieman et al. (1988) and Tromberg et al. (1990) who report
maximal shut-down within 5 min. Star et al. (1986) however,
reports a nadir occurring several hours and up to a day
post-PDT at light fluence of > 70 J cm-2. The delayed nadir
is consistent with cell swelling and interstitial edema resulting
in further perfusion impairment.
Figure 6 Tomographic studies: a, 9mTc-HMPAO planar scinti-
grams of 2 mm tumour slices. The upper two rows show five
serial sections from a tumour treated with PDT at 2400 J. The
bottom two rows show five serial sections from a control tumour
treated with light only. b, Colour-coded isodose plot of the light
dosimetry from the middle of the tumour comprising the sections
in the upper two rows of a. These measurements were taken at
the middle of the tumour perpendicular to the diffusing fibres.
The solid black line surrounding the isodose plots represents the
tumour boundary.
TableIII Perfusionshutdownin R3327-AT tumours(ratioofpost/pre
PDT 99mTc-HMPAO) for light administered at 2 and 24 h after PII
administration
2h 24h
0.325 0.418
0.399 0.673
0.274 0.494
0.471 0.582
0.652 1.000
0.414 0.769
0.493 0.699
Mean value 0.43±0.12 0.66±0.19, P = 0.02.
Conclusion
Our observations are consistent with other studies investi-
gating vascular effects of PDT using different techniques such
as: radiolabelled microspheres (Selman et al., 1984), sandwich
observation chambers (Star et al., 1986), NMR spectroscopy
(Hilf et al., 1987) and dye exclusion (Fingar et al., 1987).
Together these studies demonstrate that infarction is an
early, dose-dependent phenomenon that occurs in both well-
and poorly-differentiated tumours, as well as, in normal tis-
sue and probably accounts for the majority of tumour cell
L- .V-L.A _4K-A-46---J r- --I
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kill observed following in vivo PDT. Our data demonstrate
the utility of a non-invasive assay that can provide both
morphological and functional information by a clinically
acceptable technique. SPECT imaging of 'mTc-HMPAO
would be particularly useful for monitoring the degree and
volume of PDT induced perfusion shut-down. However,
improved photosensitisers which can be activated by longer
wavelengths (more penetrating) of light are needed to
facilitate treating tumours of clinically detectable volumes.
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